What is Biohaven's cumulative cost basis?

Biohaven (BHVN) reported cumulative cost basis of $150.53M in Q1 2026.

How has Biohaven's cumulative cost basis changed year-over-year?

Biohaven's cumulative cost basis decreased by 32.9% year-over-year, from $224.29M to $150.53M.

What is the long-term trend for Biohaven's cumulative cost basis?

Over 3 years (2022 to 2025), Biohaven's cumulative cost basis has grown at a -28.4% compound annual growth rate (CAGR), from $310.51M to $114.11M.

Biohaven BHVN Cumulative Cost Basis

Cumulative Cost Basis at other companies

Vir Biotechnology, Inc.VIR

——

BridgeBio PharmaBBIO

——

ADMA BiologicsADMA

——

Nurix Therapeutics, Inc.NRIX

——

BiogenBIIB

——

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

See full

Market cap$2.25B-48.1%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biohaven's cumulative cost basis?: Biohaven (BHVN) reported cumulative cost basis of $150.53M in Q1 2026.
How has Biohaven's cumulative cost basis changed year-over-year?: Biohaven's cumulative cost basis decreased by 32.9% year-over-year, from $224.29M to $150.53M.
What is the long-term trend for Biohaven's cumulative cost basis?: Over 3 years (2022 to 2025), Biohaven's cumulative cost basis has grown at a -28.4% compound annual growth rate (CAGR), from $310.51M to $114.11M.